Metered Dose Inhalers Market

Increasing product launch by market players

The increasing availability of new metered dose inhaler (MDI) products is a key driver of growth in the global MDI market. These launches bring about technological advancements such as improved drug delivery systems and ergonomic designs, which cater to patient preferences for ease of use and adherence. Novel formulations and combinations offer more therapeutic options for a variety of respiratory conditions, improving treatment efficacy and patient outcomes. Competitive dynamics among pharmaceutical companies drive innovation and affordability, providing healthcare providers and patients with a wider range of high-quality MDI options.

Furthermore, strategic market expansion into new geographies and targeted solutions for specific patient populations drive market growth, making MDI products indispensable in the management of respiratory diseases around the world.

For instance, in February 2022, Aptar Pharma (US) launched HeroTracker Sense, a cutting-edge digital health solution that aims to convert standard metered dose inhalers (pMDIs) into smart, connected healthcare devices. This innovation aims to improve the management and adherence of patients with chronic respiratory diseases such as asthma, COPD, cystic fibrosis, and respiratory conditions exacerbated by COVID-19. HeroTracker Sense attaches to an MDI canister and includes advanced sensors to monitor critical aspects of inhalation technique and medication adherence. In 2020, Zydus Cadila (India) launched Forglyn pMDI, India's first pressurized metered dose inhaler (pMDI) for patients with chronic obstructive pulmonary disease.

These innovations, exemplified by products like Aptar Pharma’s HeroTracker Sense and Zydus Cadila’s Forglyn pMDI, cater to diverse respiratory conditions, improving treatment efficacy and patient outcomes worldwide. Competitive dynamics foster innovation and affordability, expanding market reach and reinforcing MDIs as essential tools in managing respiratory diseases globally.

Metered Dose Inhalers Market

The Global Metered Dose Inhalers Market Industry is projected to experience robust growth in the coming years. With an estimated market value of 17.1 USD Billion in 2024, the industry is expected to expand significantly, reaching 36.2 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate (CAGR) of 7.05% from 2025 to 2035, driven by factors such as technological advancements, increasing prevalence of respiratory diseases, and supportive regulatory environments. These projections indicate a promising future for the metered dose inhalers market.

The aging population worldwide is a significant driver of the Global Metered Dose Inhalers Market Industry. Older adults are more susceptible to respiratory diseases, necessitating effective management solutions. As the geriatric demographic expands, the demand for metered dose inhalers is expected to rise correspondingly. This trend is particularly relevant in regions with rapidly aging populations, where healthcare systems are adapting to meet the needs of older patients. The market is projected to experience a compound annual growth rate (CAGR) of 7.05% from 2025 to 2035, reflecting the increasing reliance on inhalation therapies among older adults.

The Global Metered Dose Inhalers Market Industry benefits from heightened awareness and education regarding respiratory health. Public health campaigns and educational initiatives are informing patients and healthcare providers about the importance of proper inhaler technique and adherence to prescribed therapies. This increased understanding is likely to lead to higher utilization rates of metered dose inhalers, ultimately contributing to improved health outcomes. The market's growth trajectory is supported by this trend, as more individuals seek effective solutions for managing their respiratory conditions.

The Global Metered Dose Inhalers Market Industry experiences growth driven by the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). According to health statistics, millions of individuals worldwide are affected by these conditions, necessitating effective management strategies. The demand for metered dose inhalers, which deliver medication directly to the lungs, is expected to rise significantly. In 2024, the market is projected to reach 17.1 USD Billion, reflecting the urgent need for accessible and efficient treatment options for respiratory ailments.

Innovations in inhaler technology are propelling the Global Metered Dose Inhalers Market Industry forward. Enhanced designs, such as breath-actuated inhalers and smart inhalers equipped with digital tracking capabilities, are improving patient adherence and medication delivery efficiency. These advancements not only optimize the therapeutic effects of inhaled medications but also empower patients to manage their conditions more effectively. As a result, the market is anticipated to grow, with projections indicating a rise to 36.2 USD Billion by 2035, showcasing the potential of technology to transform respiratory care.

Supportive regulatory frameworks and favorable reimbursement policies are fostering growth in the Global Metered Dose Inhalers Market Industry. Governments and health organizations are recognizing the importance of accessible respiratory therapies, leading to policies that facilitate the approval and reimbursement of metered dose inhalers. This regulatory environment encourages manufacturers to innovate and expand their product offerings, ultimately benefiting patients. As a result, the market is poised for growth, with projections indicating a substantial increase in value over the coming years.

Based on region, the Global Metered Dose Inhaler Market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest market share in 2023. However, Asia-Pacific is projected to grow at the highest CAGR during the forecast period, 2024-2032

The Metered Dose Inhalers market in North America is characterized by robust growth driven by technological advancements, a supportive regulatory environment, and increasing healthcare needs. Moreover, sophisticated healthcare infrastructure and substantial investment in research and development, enabling the creation of cutting-edge Metered Dose Inhalers drives the market. Furthermore, rising awareness and education campaigns about respiratory health and inhaler usage and development of eco-friendly and sustainable propellants for metered dose inhalers present avenues for growth. Moreover, strategic partnership and collaborations are fuelling the demand for metered dose inhalers in North America.

For instance, in February 2022, Honeywell collaborated with AstraZeneca to create and market next-generation respiratory inhalers that treat asthma and chronic obstructive pulmonary disease (COPD) using propellants with near-zero global warming potential (GWP).

The Americas region is followed by Europe, which is further segmented into the Germany, France, UK, Italy, Spain, and Rest of the Europe. The Metered Dose Inhalers market in Europe is marked by increasing healthcare expenditure and well-established healthcare infrastructure. The comprehensive insurance coverage and reimbursement policies for respiratory treatments and established market presence of leading pharmaceutical companies and research institutions—are propelling the demand for Metered Dose Inhalers market. The increasing prevalence of respiratory diseases, driven by an aging population, further amplifies the need for sophisticated, high-quality metered dose inhalers.

For instance, according to European Commission, On January 1, 2023, the EU population was anticipated to be 448.8 million individuals, with more than one-fifth (21.3%) of those aged 65 years or older.

Asia-Pacific is expected to witness significant growth and is projected to be the fastest growing region over the forecast period and experiencing robust growth driven by several key factors. Rapid growing healthcare infrastructure and increasing investments in healthcare infrastructure across countries like China, India, and Japan are fueling demand for sophisticated inhalers. The rising prevalence of respiratory diseases, and an aging population further drive the need for innovative solutions.  For instance, as per the Asia-Pacific Report on Population Ageing 2022, there were approximately 670 million people aged 60 or older in Asia-Pacific in 2022.

Also, it has been estimated that the number will double to approximately 1.3 billion people by 2050 in Asia-Pacific. Additionally, the region’s growing focus on enhancing healthcare access and affordability creates significant opportunities for Metered Dose Inhalers. Favorable regulatory environments in emerging markets and supportive government initiatives also contribute to market expansion. Furthermore, strategic partnerships and collaborations with local medical device manufacturers enhance the ability of Metered Dose Inhalers to scale operations and meet the diverse needs of the regional market.

FIGURE 3: METERED DOSE INHALERS MARKET BY REGION 2023 & 2032 (USD BILLION)

The global metered dose inhaler market is distinguished by the presence of numerous regional and local players catering to the global metered dose inhaler market. Furthermore, the increasing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis, continuous innovations in inhalation device technology, including improvements in aerosol delivery systems, propellants, and dose counters, increase the efficacy, safety, and convenience of use of MDIs, and many patients prefer inhalation therapy to oral drugs because of its focused distribution to the lungs, quick beginning of action, and fewer systemic side effects.

This preference motivates the acceptance of MDIs as a preferred alternative for addressing respiratory diseases and is further driving the growth of the global metered dose inhaler market during the forecast period.

The global metered dose inhaler market is extremely competitive, with players competing and investing heavily in development of innovative products to gain a significant market share. The market is moderately fragmented with high competition in the market, increasing partnerships, and introducing new products and increasing portfolio attractiveness.

The growth of prominent industry players is dependent on various factors, such as market conditions, product differentiation and innovation, and pricing strategies. It is also projected that a rise in the investments for new product launches and the shift towards online purchasing will also boost the market's growth in the upcoming future.

Lupin Pharmaceuticals is one of the largest generic pharmaceutical companies in the world, with a significant presence in over 100 countries and offering a diverse portfolio of over 1000 products. It is known for its expertise in developing, manufacturing, and marketing a wide range of generic and branded pharmaceuticals, as well as active pharmaceutical ingredients (APIs) across various therapeutic segments. They are expanding their portfolio with complex generics platforms focused on inhalation, injectables, and biosimilars.

In July 2023, Hormosan Pharma GmbH, Lupin's German subsidiary, has launched Luforbec100/6 (beclometasone 100µg / for moterol 6µg), a pressurized metered dose inhaler (pMDI) for treating adult asthma and chronic obstructive pulmonary disease (COPD) in Germany.